Leading mRNA biotech companies' net income 2022
In 2020, U.S. mRNA specialist Moderna reported a net loss of around 750 million U.S. dollars. Two years later, and thanks to the success of its COVID-19 vaccine Spikevax, it was around 8.4 billion U.S. dollars.
The use of mRNA as a drug takes a fundamentally different approach to treating diseases than other drug classes. mRNA is the instruction that cells in the human body use to make proteins and send them to various locations in the body. mRNA drugs make use of normal biological processes to create proteins and achieve the desired therapeutic effect. This enables the potential treatment of a wide variety of diseases, many of which cannot be treated with current technologies.
The use of mRNA as a drug takes a fundamentally different approach to treating diseases than other drug classes. mRNA is the instruction that cells in the human body use to make proteins and send them to various locations in the body. mRNA drugs make use of normal biological processes to create proteins and achieve the desired therapeutic effect. This enables the potential treatment of a wide variety of diseases, many of which cannot be treated with current technologies.
